MBX$44.17
Chart
Performance
Key Stats
AI MBX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldMBX Biosciences shows promising development in its pipeline, particularly for endocrine and metabolic disorders. However, its early clinical stage, lack of revenue, and negative earnings translate to significant risk. The company has a healthy cash position, but continued financing will be crucial. Technicals suggest short-term volatility, while thematic alignment with biopharmaceutical innovation is present but not yet generating financial returns.
Thematic
MBX Biosciences operates in the biopharmaceutical sector, focusing on precision peptide therapies for endocrine and metabolic disorders, aligning with the growing interest in personalized medicine and chronic disease management.
Fundamental
As a clinical-stage company with no current revenue and significant operating expenses, MBX Biosciences exhibits weak fundamental performance metrics. Its financial health relies heavily on its cash reserves and future financing, with a substantial negative EPS.
Technical
The stock has experienced significant volatility, with recent price action showing recovery after a substantial decline. While moving averages are mixed across different timeframes, some indicators suggest potential upward momentum, though resistance levels are evident.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 85 |
| Chronic Disease Management | 80 |
| Biotech Investment Trends | 65 |
| Regulatory Landscape | 70 |
| Peptide Therapeutics | 75 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 80 |
| Balance Sheet Health | 95 |
| Cash Flow | 10 |
| Earnings Per Share (EPS) | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
| Short-term Indicators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Improving Cash Position
Cash equivalents have increased significantly from $24.21M in Q4 2022 to $49.35M in Q4 2024, indicating enhanced financial flexibility.
Strengthened Balance Sheet
Total assets have grown from $45.095M in Q4 2022 to $268.535M in Q4 2024, with a corresponding decrease in liabilities relative to assets, suggesting a healthier financial structure.
Bearish Points (9)
Negative Revenue and Net Income
The company reported zero total revenue and a significant net loss of -$61.922M in Q4 2024, with negative net margins across all reported periods, indicating a lack of commercialization and profitability.
High Valuation Without Revenue
Despite zero revenue, the company has a market capitalization of $484.32M, resulting in a Price/Sales (P/S) ratio of 0.0, which, in the absence of sales, implies a valuation based purely on future potential and is highly speculative.
Calendar
August 2025
7
Next Earnings Date
H: $-0.74
A: $-0.75
L: $-0.75
Profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Seasonals
Price Target
37.50 USD
The 39 analysts offering 1 year price forecasts for MBX have a max estimate of 44.00 and a min estimate of 30.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor and industry peer focusing on enterprise servers, storage, networking, and IT services, fundamental to data center infrastructure.
Weight: 90
Major player in enterprise servers, storage, workstations, and network solutions, directly competing in the IT infrastructure market.
Weight: 88
Provides comprehensive enterprise IT solutions, including hybrid cloud, AI, software, and consulting, deeply embedded in large-scale IT infrastructure.
Weight: 85
Dominant provider of networking hardware, software, and services crucial for building and connecting enterprise data centers and IT environments.